Key Takeaways
- UnitedHealth Group (UNH) stock gained approximately 11% in the month through October 30, supported by stronger third-quarter earnings and another increase to its 2026 profit outlook.
- Operating earnings climbed to $6.6 billion, while Optum Health’s operating profit reached $735 million, although declining insurance membership remains a concern.
- Analysts expect normalized EPS to recover to $26.99 by 2028, while shares trade at an estimated 18x forward earnings, suggesting further upside if margins continue improving.
What Happened?
UnitedHealth Group (UNH) stock gained approximately 11% between September 30 and October 30, climbing from $367 to $407, while the Nasdaq 100 declined 7% and the S&P 500 slipped 1%.
The rally followed UnitedHealth’s October 13 third-quarter earnings announcement, which showed improving profitability despite continued pressure on health insurance membership.
UnitedHealth reported adjusted earnings of $4.69 per share, beating analysts’ expectations of approximately $4.14. Revenue reached $112.7 billion, down slightly from $113.2 billion a year earlier.
The company also raised its full-year 2026 adjusted earnings outlook to at least $20.50 per share, marking its third guidance increase of the year.
Its medical care ratio improved to 88.4% from 89.9% a year earlier, reflecting better medical cost management and pricing discipline.
CEO Stephen Hemsley said the results reflected “the discipline and execution our teams are bringing to every part of our business.”
Mizuho named UnitedHealth a top pick on October 14, while a broader rotation from technology stocks into healthcare supported managed-care companies. On October 20, RBC Capital Markets raised its price target from $478 to $498 while maintaining an Outperform rating.
Quarterly earnings from operations rose to $6.6 billion from $4.3 billion a year earlier, bringing UnitedHealth’s operating margin to approximately 5.9%.
Optum Health contributed significantly to that improvement, generating $735 million in operating earnings compared with just $41 million in the prior-year quarter.
UnitedHealth’s operating margin exceeded 8% annually from 2021 through 2024 before falling to 4.8% in 2025. Based on annual revenue of approximately $448 billion, every percentage point of margin recovery could represent roughly $4.5 billion in additional operating profit, assuming comparable revenue.
However, the quarter benefited from $610 million in favorable reserve development. Excluding that benefit, the medical care ratio would have been approximately 89.1%, still better than the year-earlier quarter.
UnitedHealthcare served 48.3 million people at the end of September, down from 50.1 million a year earlier. The company is also discontinuing plans affecting approximately 390,000 Medicare Advantage members as it prioritizes profitability.
The central question is whether continued margin improvements can offset a smaller membership base and sustain earnings growth.
Is UnitedHealth Stock Undervalued or Overvalued?
UnitedHealth appears undervalued based on its expected earnings recovery and historical valuation, although further upside depends on sustained operating improvements.
According to TIKR consensus estimates as of October 21, normalized EPS is expected to recover from $16.35 in 2025 to $23.27 in 2027 and $26.99 in 2028, approaching the $27.66 recorded in 2024.
Management indicated that approximately 13% earnings growth, the lower end of its long-term 13% to 16% growth framework, is a reasonable starting point for 2027.
UnitedHealth’s forward P/E has averaged approximately 19x over the past five years and reached roughly 25x in April 2022.
At its October 30 closing price near $407, UnitedHealth traded at an estimated 18x forward earnings based on earlier TIKR valuation data. TIKR’s October 22 consensus analyst price target of approximately $478 implied about 17% upside.
The earnings recovery also supports the investment case discussed in TIKR’s earlier analysis of UnitedHealth’s third-quarter results.
However, continued membership losses and potential Medicare Advantage reimbursement changes remain important risks. Raymond James lowered its price target to $450 amid regulatory concerns, highlighting uncertainty surrounding future profitability.
UnitedHealth appears undervalued, making additional purchases more compelling than taking profits at current levels. However, slower margin recovery or further membership losses could limit future gains.
So what is UnitedHealth stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what UnitedHealth could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
